Similarly, the expressions of NOTCH target genes (Hes1, Hes5, and Hey1, among others) in U2OS and 143B osteosarcoma cells treated with sublethal doses of cisplatin were significantly higher than those of cisplatin-sensitive cells [49]. This evidence concerns the gene HES1 and osteosarcoma.